Evoke Pharma Statistics

Total Valuation

Evoke Pharma has a market cap or net worth of $4.57 million. The enterprise value is -$137,530.

Market Cap	4.57M
Enterprise Value	-137,530

Important Dates

The next estimated earnings date is Thursday, August 8, 2024, before market open.

Earnings Date	Aug 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Evoke Pharma has 8.60 million shares outstanding. The number of shares has increased by 171.67% in one year.

Shares Outstanding	8.60M
Shares Change (YoY)	+171.67%
Shares Change (QoQ)	+171.67%
Owned by Insiders (%)	9.51%
Owned by Institutions (%)	36.80%
Float	4.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.75
Forward PS	0.37
PB Ratio	1.31
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.39, with a Debt / Equity ratio of 1.43.

Current Ratio	1.39
Quick Ratio	1.25
Debt / Equity	1.43
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-13.22

Financial Efficiency

Return on equity (ROE) is -4,897.70% and return on invested capital (ROIC) is -79.76%.

Return on Equity (ROE)	-4,897.70%
Return on Assets (ROA)	-78.40%
Return on Capital (ROIC)	-79.76%
Revenue Per Employee	$1.53M
Profits Per Employee	-$1.78M
Employee Count	4
Asset Turnover	0.67
Inventory Turnover	0.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.31% in the last 52 weeks. The beta is 0.37, so Evoke Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	-69.31%
50-Day Moving Average	0.51
200-Day Moving Average	0.80
Relative Strength Index (RSI)	48.21
Average Volume (20 Days)	22,967

Short Selling Information

The latest short interest is 11,304, so 0.13% of the outstanding shares have been sold short.

Short Interest	11,304
Short Previous Month	24,752
Short % of Shares Out	0.13%
Short % of Float	0.25%
Short Ratio (days to cover)	0.41

Income Statement

In the last 12 months, Evoke Pharma had revenue of $6.11 million and -$7.13 million in losses. Loss per share was -$1.83.

Revenue	6.11M
Gross Profit	5.86M
Operating Income	-6.78M
Pretax Income	-7.13M
Net Income	-7.13M
EBITDA	-6.54M
EBIT	-6.63M
Loss Per Share	-$1.83

Full Income Statement

Balance Sheet

The company has $9.70 million in cash and $5.00 million in debt, giving a net cash position of $4.70 million or $0.55 per share.

Cash & Cash Equivalents	9.70M
Total Debt	5.00M
Net Cash	4.70M
Net Cash Per Share	$0.55
Equity (Book Value)	3.50M
Book Value Per Share	0.41
Working Capital	3.50M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-5.93M
Capital Expenditures	n/a
Free Cash Flow	-5.93M
FCF Per Share	-$0.65

Full Cash Flow Statement

Margins

Gross margin is 96.01%, with operating and profit margins of -110.99% and -116.76%.

Gross Margin	96.01%
Operating Margin	-110.99%
Pretax Margin	-116.76%
Profit Margin	-116.76%
EBITDA Margin	-107.05%
EBIT Margin	-108.55%
FCF Margin	-97.18%

Dividends & Yields

Evoke Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-171.67%
Shareholder Yield	-171.67%
Earnings Yield	-156.16%
FCF Yield	-129.97%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on May 23, 2022. It was a reverse split with a ratio of 1:12.

Last Split Date	May 23, 2022
Split Type	Reverse
Split Ratio	1:12

Scores

Evoke Pharma has an Altman Z-Score of -14.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-14.68
Piotroski F-Score	3